Program
odronextamab
Also written as “Odronextamab” and “Odronextamab multiple dose levels”.
Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis · Lymphoma, Non-Hodgkin, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Oct 13, 20238 company-led studies, 6 open or runningNext primary completion: Feb 29, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 86 open or running | phase 3since Oct 13, 2023 | Nov 7, 2014 | Feb 29, 2028phase 3 · NCT06091254 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2014First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT02290951 · 200 enrolled · United States, France, Germany and more
- Jan 5, 2016Phase 1 study in RecurrenceNCT02651662 · 105 enrolled · United States, Austria, Germany and more
- Mar 14, 2019Phase 2 study in Lymphoma, B-CellNCT03888105 · 515 enrolled · United States, Australia, Canada and more
- Oct 13, 20232 phase 3 studiesNCT06091865, NCT06091254
- Nov 20, 2023Phase 3 study in Lymphoma, FollicularNCT06149286 · 580 planned · United States, Australia, Austria and more
- Dec 29, 2023Phase 3 study in Lymphoma, B-CellNCT06230224 · 216 enrolled · Argentina, Australia, Brazil and more
- May 8, 2025Phase 1 study in Lupus NephritisNCT06975787 · 90 planned · United States, France, Germany and more
- Nov 12, 2026Primary completion moved from 2028-02-07 to 2028-02-29Date moved laterphase 3 · +1 months · NCT06091254
Ahead
- Feb 29, 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT06091254
- Mar 30, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06091865
- May 29, 2028Primary completion: phase 3 study in Lymphoma, B-CellNCT06230224
- Sep 10, 2029Primary completion: phase 1 study in Lupus NephritisNCT06975787
TargetBeta
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06975787Lupus Nephritis · United States, France, Germany and more | 1 | Recruiting | Sep 10, 2029 | 90 |
| NCT06230224Lymphoma, B-Cell · Argentina, Australia, Brazil and more | 3 | Active, not recruiting | May 29, 2028 | 216 |
| NCT06149286Lymphoma, Follicular · United States, Australia, Austria and more | 3 | Recruiting | Apr 30, 2031 | 580 |
| NCT06091865Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Recruiting | Mar 30, 2028 | 904 |
| NCT06091254Lymphoma, Follicular · United States, Australia, Austria and more | 3 | Recruiting | Feb 29, 2028 | 822 |
| NCT03888105Lymphoma, B-Cell · United States, Australia, Canada and more | 2 | Active, not recruiting | Jun 17, 2026 | 515 |
| NCT02651662Recurrence · United States, Austria, Germany and more | 1 | Completed | Apr 29, 2026 | 105 |
| NCT02290951Lymphoma, Non-Hodgkin · United States, France, Germany and more | 1 | Completed | Aug 21, 2025 | 200 |
How it is read
Names in the registry
- “Odronextamab”, 6 entries
- “Odronextamab multiple dose levels”, 2 entries
- “odronextamab”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 3 studies
- Lymphoma, Follicular, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lupus Nephritis, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.